Conflict of Interest T.A.L., J.T.C., P.J.N., J.L.M., and M.K. received funding from the Personalized Medicine Coalition for the research presented in the original publication. T.A.L. has consulted for Merck and has received compensation. J.T.C. has consulted for Biogen, IQVIA, Novartis, Partnership for Health Analytic Research, Pharmerit, Precision Health Economics, Sage Therapeutics, Sanofi, Sarepta, and RA Capital and has received compensation. P.J.N. has consulted for PRECISIONheor, Sarepta Therapeutics, and Cytokinetics and has received compensation. P.J.N. also served on the advisory board for Biogen, PhRMA Foundation, AveXis, Intercept Pharmaceuticals, Bayer, Amgen Inc, Sanofi, Panalgo, and Merck. D.P. is employed by the Personalized Medicine Coalition, a 501(c)3 nonprofit organization that provided funding for the study. B.E.S. is an employee and stockholder of Illumina, Inc. D.S., P.S.E., and S.B.W. declare no conflicts of interest.